Reven Holdings Announces the Publication of a Peer-reviewed Article in the Prestigious Medical Journal Frontiers in Oncology

Reven Holdings Also Reports That 12-patient Part 1 Completed Plus 10 Patients Already Enrolled and Dosed in Part 2 of the Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Reven’s Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

WESTMINSTER, Colo.–(BUSINESS WIRE)—Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses, including COVID-19 – and inflammatory disorders.

Reven today announced the publication of a peer-reviewed article in the prestigious medical journal Frontiers in Oncology. The article reports a systematic analysis of the antibody responses to COVID-19 vaccination in cancer patients. This analysis was completed in collaboration with the Hacettepe University Cancer Institute team in Ankara/Turkey and Ares Pharmaceuticals, LLC in St. Paul, MN. COVID-19 vaccine seroconversion rates (i.e., antibody development success) were substantially lower in patients with hematologic malignancies (example: leukemias and lymphomas) and cancer patients receiving chemotherapy or immunosuppressive treatments than controls who did not have cancer.

The article, “Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review,” has been published in Frontiers in Oncology, and it is available online. To view the online publication, click here:

Citation: Guven DC, Sahin TK, Kilickap S and Uckun FM (2021) Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. Front. Oncol. 11:759108. doi: 10.3389/fonc.2021.759108

The corresponding author, Executive Vice-President for Global Medical Affairs and Chief Medical Officer of Reven, Dr. Fatih Uckun MD PhD, explained: “We are reporting the challenges for oncology patients in achieving adaptive immunity against COVID-19. This report illustrates the importance of developing effective treatments against high-risk COVID-19 and COVID-19-associated cytokine release syndrome (CRS) considering the poor performance of vaccinations in cancer patientsReven’s clinical development efforts for our lead COVID-19 drug candidate RJX are aimed at reducing the risk of life-threatening complications of COVID-19 and accelerating the full recovery of high-risk patients, such as those with cancer.

This paper illustrates the importance of our randomized trial to address unmet needs in COVID-19 therapy,” added Peter Lange, the CEO of Reven.

Reven had recently announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of RJX in hospitalized high-risk COVID-19 patients. 12 hospitalized adult patients with symptomatic high-risk COVID-19 pneumonia and abnormally elevated inflammation markers in the blood were treated with daily intravenous infusions of RJX in combination with standard of care. Nine (9) of the 12 patients, including 3 patients with hypoxemic respiratory failure, had shown rapid clinical recovery with normalization of the abnormally elevated inflammation markers in the blood and were discharged from hospital at a median of 5 days. All patients tolerated their RJX infusions without any side effects. An Independent Data and Safety Monitoring Board (DSMB) that oversees and acts independently from the Reven project team had reviewed the clinical data in all 12 patients, and approved the initiation of the randomized, double-blind Part 2 portion of the Phase 2 study.

10 patients have already been enrolled and dosed in the randomized, double-blind, placebo-controlled Part 2 portion of the Phase 2 study ( Identifier: NCT04708340; This FDA-approved controlled clinical trial is aimed at evaluating the efficacy and safety of RJX in side-by-side comparison with a placebo as an adjunct to standard of care in hospitalized COVID-19 patients. Michael Volk, Director and Chief Strategy Officer of Reven, stated, “We are excited about the rapid progress in our clinical program against COVID-19.

We are expecting topline data from this very important study by end of 2021,” said Brian Denomme, Reven’s President.

We are diligently advancing the clinical development of RJX,” said Fatih Uckun, MD PhD.

RJX is an intravenous (IV) formulation of a patented first-in-class pharmaceutical composition containing a specific mixture of antioxidant and anti-inflammatory ingredients that is being developed for more effective treatment of patients with inflammatory disorders, including COVID-19 patients with viral sepsis, multi-system inflammation, cytokine release syndrome (CRS), shock, ARDS, and multi-organ failure. The FDA-approved clinical trial is aimed at evaluating the efficacy and safety of RJX as an adjunct to standard of care in hospitalized COVID-19 patients, who have high-risk features for progression to severe disease and ARDS and patients with hypoxemic respiratory failure receiving either non-invasive positive pressure ventilation (NIPPV) or high flow oxygen, who have not yet developed ARDS to require mechanical ventilation. Since RJX is a potent anti-oxidant and anti-inflammatory agent that has been shown to reduce the tissue-level oxidative stress in multiple organs in animal models of severe systemic inflammation, shock, cytokine storm, and multiorgan failure, Reven hopes that it will contribute to prevention of progression of COVID-19 and its faster resolution in high-risk patients.

About Rejuveinix (RJX)

RJX is an intravenous (IV) formulation of physiologically compatible compounds that is being developed for more effective treatment of patients with sepsis, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS).

About Reven Holdings, Inc.

Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering from PAD and other cardiovascular related medical conditions.

Reven’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “on-track”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the company’s periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information regarding future events, or otherwise.


Michael Volk, Chief Strategy Officer